Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 15/20 | 0.39 |
| ▸ | MME | P08473 | 6/20 | 0.39 |
| ▸ | AGTR2 | P50052 | 13/20 | 0.34 |
| ▸ | ECE1 | P42892 | 1/20 | 0.34 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL653979 | 0.91 | MME (0.42) | AGTR1MMEAGTR2 | |
| SCHEMBL653014 | 0.89 | MME (0.38) | AGTR1MME | |
| SCHEMBL652695 | 0.88 | MME (0.43) | AGTR1MMEAGTR2ECE1BDKRB1 | |
| SCHEMBL652998 | 0.86 | MME (0.49) | AGTR1MMEAGTR2ECE1 | |
| SCHEMBL1927466 | 0.86 | MME (0.49) | AGTR1MMEAGTR2ECE1 | |
| SCHEMBL652672 | 0.85 | MME (0.42) | MME | |
| SCHEMBL652673 | 0.85 | MME (0.42) | MME | |
| SCHEMBL3702552 | 0.84 | AGTR1 (0.40) | AGTR1AGTR2BDKRB1 | |
| SCHEMBL651498 | 0.83 | MME (0.39) | AGTR1MMEAGTR2 | |
| SCHEMBL651499 | 0.83 | MME (0.39) | AGTR1MMEAGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119634-B2 | Dual-acting pyrazole antihypertensive agents | THERAVANCE, INC. (US) | 2012-02-21 | — | — | US | disclosed |
| US-20110275634-A1 | DUAL-ACTING PYRAZOLE ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2011-11-10 | — | — | US | disclosed |
| US-7956054-B2 | Dual-acting pyrazole antihypertensive agents | THERAVANCE, INC. (US) | 2011-06-07 | — | — | US | disclosed |
| US-20110009409-A1 | DUAL-ACTING PYRAZOLE ANTIHYPERTENSIVE AGENTS | THERAVANCE BIOPHARMA R&D IP, LLC | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009409-A1 | DUAL-ACTING PYRAZOLE ANTIHYPERTENSIVE AGENTS | AGTR1, AGTR2, REN | AGTR1 1/4885MME 10/4885AGTR2 2/4885 |
| US-20110275634-A1 | DUAL-ACTING PYRAZOLE ANTIHYPERTENSIVE AGENTS | AGTR1, REN, AGTR2 | AGTR1 1/4885MME 13/4885AGTR2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.